Skip to main content
. Author manuscript; available in PMC: 2022 Aug 3.
Published in final edited form as: Ann Oncol. 2020 Nov 21;32(2):229–239. doi: 10.1016/j.annonc.2020.11.007

Fig 2. Association between ctDNA and clinicopathologic characteristics.

Fig 2.

A) Overview of patient and tumor characteristics according to ctDNA status at baseline (T0). HR-hormone receptor, TNBC-triple negative breast cancer, pCR- pathological complete response. B) Proportion of ctDNA-positive and negative patients at baseline (T0) according to clinical characteristics. P values were calculated using Fisher’s exact test. C) Mean tumor molecules per mL of plasma according to clinical characteristics. Distributions were compared using Wilcoxon rank sum (binary variable) or Kruskal Wallis (ternary variable) tests.